Nicotine Replacement Therapy Inpatient Prescribing Guideline
|
|
- Julian Jones
- 5 years ago
- Views:
Transcription
1 SH CP 187 Nicotine Replacement Therapy Inpatient Prescribing Guideline Summary: Nicotine replacement therapy prescribing guideline (does not cover e-cigarettes and similar products) Keywords (minimum of 5): (To assist policy search engine) Nicotine replacement therapy, NRT, smoking, smokefree, smoking ban, smoking abstinence, cigarettes, vape Target Audience: All prescribers, pharmacists, pharmacy technicians, nurses, healthcare support workers, mental health practitioners, occupational therapists. Next Review Date: September 2020 Approved & Ratified by: Medicines Management Committee Date of meeting: 19 th Date issued: November 2018 Author: Gillian Ritchie, Clinical Pharmacist Sponsor: Karl Marlowe, Medical Director 1
2 Version Control Change Record Date Author Version Page Reason for Change 20/03/17 Glenis Clifford 1 9 NRT costs 20/03/17 Francis Johnson 1 5 Added if patient is on, Added 24 and 16 hour patch information, amend the signs 03/05/17 Francis Johnson 1 10 Changed the smoking and interactions with medication table 6/6/17 Gillian Ritchie 1 5 Adjusted the signs alongside the quickmist oral spray and inhalator, to reflect current costings. 6/6/17 Gillian Ritchie 1 10 Changed the smoking and interactions with medication table back to the original version from Version 1 as this is more comprehensive and accurate (and checked it still reflects current evidence). 13/6/17 Gillian Ritchie 1 5 Added the words contraindications, adverse effects of the preparations to the second box from the top, where it states to choose NRT products based on patient preference, level of dependence, previous use of NRT 13/6/17 Gillian Ritchie 1 5 Added the words at least seven days to the sentence advising to avoid using the same site (for nicotine patch) for at least seven days. 13/6/17 Gillian Ritchie 1 5 Added, acidic drinks such as coffee or fruit juice may decrease the absorption of nicotine through the buccal mucosa and should be avoided for 15 minutes before the use of oral NRT. 13/6/17 Gillian Ritchie 1 5 Added care should be taken to avoid spraying into the eyes in the administration section for nicotine oral spray. 13/6/17 Gillian Ritchie 1 5 Added if an adverse event occurs with a high strength lozenge, a lower strength lozenge should be considered instead. If attempting smoking cessation, treatment should continue for 6 12 weeks before attempting a reduction in dose. Use beyond 6 months is generally not recommended in the nicotine lozenge section. 13/6/17 Gillian Ritchie 1 5 Added until the taste becomes strong. The lozenge should then be lodged between the gum and the cheek. When the taste fades, the lozenge should be sucked again this should be repeated until the lozenge dissolves completely. To the administration section for the nicotine lozenge. 13/6/17 Gillian Ritchie 1 5 Added place the cartridge in the device to the administration section for nicotine inhalation cartridge. 13/6/17 Gillian Ritchie 1 5 Deleted suggest the patient experiments with what suits them best, eg 5 or 10 minute inhalation periods and replaced it with each session can last for approximately five minutes. 13/6/17 Gillian Ritchie 1 5 Deleted note that a bottle of Quickmist spray lasts for approximately 72 hours and so one bottle may be given to the patient every 72 hours if necessary and replaced it with: note that a bottle of Quickmist spray contains at least 150 sprays. The maximum dose is 64 spays in 24 hours. 13/6/17 Gillian Ritchie 1 11 Added and / or who have uncontrolled hypertension to the section on cardiovascular / cerebrovascular disease. 13/6/17 Gillian Ritchie 1 11 Added and obstructive lung disease to the section on lung disease. 13/6/17 Gillian Ritchie 1 11 Added sections regarding precautions for using NRT in people with seizures, broken skin / skin disorders and atopic or eczematous dermatitis. 13/6/17 Gillian Ritchie 1 12 Added increased salivation and blurred vision to the side effects table. 13/6/17 Gillian Ritchie 1 All Added references throughout guideline. 13/6/17 Gillian Ritchie 1 All Reviewed entire guideline to ensure it reflects current evidence. 19/6/17 Gillian Ritchie 1 5 Deleted the words choose one with respect to use of short-acting NRT preparations 10/07/17 Gillian Ritchie 2 8 Added the Melbury Lodge record. 11/09/17 Alex Weston 2 5 Added text restricted use, not to be used for new patients from Oct 1 st /09/17 Alex Weston 2 6 Removed Quick Mist spray from chart and added as 2b on page 7 20/09/17 Alex Weston 2 5 Added 6 months maximum supply of NRT products 25/7/18 Rebecca Henry 3 Through out Melbury Lodge changed to EPMA sites Nicotine inhalator, not to be used a t leigh House Only 16 hours patch to be used at leigh House Melbury lodge discretionary meds paper chart removed Order details added Add if using e cigarettes or vapes to avoid prescribing short acting preparations 2
3 Reviewers/contributors Name Position Version Reviewed & Date Gillian Ritchie Pharmacist V1 December 2015 Vanessa Lawrence Principal pharmacist V1 December 2015 Sue Mills Chief Pharmacist V1 December 2015 Marion Wetherill Principal Pharmacist V1 December 2015 All AMH Consultant Psychiatrists V1 December 2015 All Consultant Forensic Psychiatrists adult V1 December 2015 Mental health drugs and therapeutics committee V1 December 2015 Julia Robson Clinical Service Manager- Quit4life V1 December 2015 Wendy Bennett Operational Service Manager Quit4life V1 December 2015 Glenis Clifford Clinical Lead Quit4Life Version 1 March 2017 Francis Johnson Deputy Chief Pharmacist Version 1 March 2017 Rebecca Henry Principal Pharmacist Specialised Version 1 March 2017 and Training Gillian Ritchie Clinical Pharmacist Version 1 June 2017 Ishtiaq Hussian Specialist registrar, Leigh House Sept
4 Contents Section Title Page 1. Nicotine replacement therapy prescribing algorithm 5 2. As required short-acting nicotine replacement therapy prescription and administration chart Nicotine replacement therapy products and prices 8 4. Ordering process 9 5. Smoking and interactions with medication (discussion) Smoking and interactions with medication (table) Precautions for use of NRT Side effects of NRT Use of NRT in pregnancy / lactation References 14 4
5 1. Nicotine replacement therapy prescribing algorithm SHFT will supply NRT products for a maximum of 6 months Assess level of nicotine dependence. Consider: How many cigarettes a day does the person usually smoke? Patient choice of NRT product How soon after waking does the person have his / her first cigarette? Known allergies to NRT products Previous use of NRT Current medical conditions If patient is on clozapine, obtain level and adjust dose as per Trust clozapine guideline (CP 114) (1). Check GASS for clozapine and increase physical observations. Refer to appendix 8 of this guideline for details of dose adjustments required for other medication when stopping / abstaining from smoking Choose NRT products based on patient preference, level of dependence, previous use of NRT, contraindications, adverse effects of the preparations, nicotine withdrawal and cravings (2) Light smoker Smokes fewer than 10 cigarettes daily Moderate / heavy smoker Smokes more than 10 cigarettes daily (2, 3, 4, 5) Nicotine patch 14mg / 24 hours for 6 8 weeks then 7mg / 24 hours for 2 4 weeks OR 15mg / 16 hours Invisi patch for 6 8 weeks then 10mg / 16 hours Invisi patch for 2 4 weeks (2, 3, 4, 5) Nicotine patch 21mg / 24 hours for 6 8 weeks then 14mg / 24 hours for 2 weeks then 7mg / 24 hours for 2 weeks OR 25mg / 16 hours Invisi patch for 8 weeks then 15mg / 16 hours Invisi patch for 2 weeks then 10mg / 16 hours Invisi patch for 2 weeks NOTE: if a patient is abstaining from smoking only for the duration of his / her hospital stay (rather than stopping smoking long-term), it would be appropriate for him / her to continue on the higher dose patch whilst in hospital, and not to attempt the reducing dosage regimen detailed above. Apply the patch on waking to dry, non-hairy skin on the hip, trunk or upper arm (2, 3, 4, 5, 6). Hold in position for seconds to ensure adhesion (2) For the 24 hour patch: Remove the patch the following day and place a new patch on a different area (2, 3, 4, 5). Avoid using the same site for at least seven days (2, 3, 4, 5, 6). For the 16 hours patch: Apply on waking in the morning and remove at bedtime (2). Avoid using on the same site for several days. Leigh House to only use the 16hour patches and only for 12 weeks If the person experiences strong cravings for cigarettes upon waking, a 24 hour patch may be more suitable (2) If withdrawal symptoms are experienced, the strength of the patch should be maintained or increased until the patient is stabilised (2). If a patient using the high-strength patch experiences excessive side effects that do not resolve within a few days, he / she should be changed to a medium-strength patch for the remainder of the initial treatment period and then use the lower strength patch for 2 4 weeks (2, 3, 4, 5, 6). Monitor and review on an ongoing basis to ensure effectiveness. Combine with a short-acting preparation Not to be prescribed if the patient is using electronic cigarettes or vapes Acidic drinks such as coffee or fruit juice may decrease the absorption of nicotine through the buccal mucosa and should be avoided for 15 minutes before the use of oral NRT (2). Nicotine lozenge 1mg / 2mg / 4mg Dose: One lozenge every 1 2 hours when the urge to smoke occurs (2, 10, 11). Max 15 lozenges / 24 hours. Individuals who smoke fewer than 20 cigarettes daily should use the lower strength lozenges (2, 10). Individuals who smoke more than 20 cigarettes daily and those who fail to stop smoking with the low-strength lozenges should use 4mg lozenges (2, 11). For all other individuals, the 1mg or 2mg lozenges should be used. If an adverse event occurs with a high strength lozenge, a lower strength lozenge should be considered instead (10). If attempting smoking cessation, treatment should continue for 6 12 weeks before attempting a reduction in dose (BNF). Use beyond 6 months is generally not recommended (10). Administration: Allow the lozenge to dissolve slowly in the mouth until the taste becomes strong (10, 11). The lozenge should then be lodged between the gum and the cheek (10, 11). When the taste fades, the lozenge should be sucked again (10, 11). From time to time, move the lozenge from one side of the mouth to the other (2). This routine should be repeated until the lozenge dissolves completely (10). Try not to swallow excessively as the nicotine needs to be absorbed through the buccal mucosa. Lozenges last for minutes (2, 10). OR Nicotine inhalation cartridge., not to be used at Leigh House Dose: Max 6 cartridges / 24 hours Administration: Place the cartridge in the device and draw in air through the mouthpiece (2). Each session can last for approximately five minutes (2). The amount of nicotine from one puff of the cartridge is less than that from a cigarette (2, 12). Therefore it is necessary to inhale more often than when smoking a cigarette (2). A 15mg cartridge lasts for approximately 40 minutes of intense use (2, 12). One cartridge 4 6 normal strength cigarettes. OR Nicotine Oral spray (Quickmist mouthspray) restricted use, not to be used for new patients from Oct 1 st Particularly good for heavier smokers - faster onset of action compared with other products. Dose: 1 2 sprays in the mouth (up to 4 sprays / hour) when the urge to smoke occurs or to prevent cravings (2, 9). Max 64 sprays / 24 hours Administration: The oral spray should be released into the mouth, holding the spray as close to the mouth as possible (9) and avoiding the lips (2). Release one spray into the side of the mouth. The patient should not inhale while spraying and should avoid swallowing for a few seconds after use (2, 9). If using the spray for the first time, or if it has not been used for 2 or more days, prime the unit before use (2) (point the spray away from the user or other people and press the top of the device 3 times until a fine spray appears) (9) Care should be taken to avoid spraying into the eyes (9). (7, 8) 5
6 2a. As required short-acting nicotine replacement therapy prescription and administration chart (EPMA sites USE JAC ELECTRONIC PRESCRIBING SYSTEM, SEE BELOW) Ward Allergy / sensitivity Clinician s signature Date Surname First name Consultant Date of birth If none known, endorse NKDA Patient s NHS number Prescribe a nicotine patch on the main prescription chart. Prescribe ONE of the following short-acting nicotine replacement products on an as required basis, and cross through the other product. Following an individual risk assessment, patients may be given up to 24 hours supply of prn NRT as per MCAPP (CP1). It should be labelled with the patient s name and may be kept on the patient for self-administration. The quantity given should be documented below in addition to the date/time/initials Nicotine lozenge Dose interval (minimum) 1 2 hours OR Nicotine inhalation cartridge Dose interval (minimum) 1 2 hours Dose 1mg / 2mg / 4mg (circle) Route Oral Max 15 lozenges in 24 hours Dose 15mg Route Oral Signature Date Signature Date Max 6 cartridges in 24 hours Date Time Dose Initial Date Time Dose Initial 6
7 2b. As required short-acting nicotine replacement therapy prescription and administration chart, Quickmist Spray (EPMA sites USE JAC ELECTRONIC PRESCRIBING SYSTEM, SEE BELOW ) Restricted use, not to be used for new patients from Oct 1 st 2017 Ward Allergy / sensitivity Clinician s signature Date Surname First name Consultant Date of birth If none known, endorse NKDA Patient s NHS number Note that a bottle of Quickmist spray contains at least 150 sprays (9). The maximum dose is 64 sprays in 24 hours. Prescribe a nicotine patch on the main prescription chart. Following an individual risk assessment, patients may be given up to 24 hours supply of prn NRT as per MCAPP (CP1). It should be labelled with the patient s name and may be kept on the patient for self-administration. The quantity given should be documented below in addition to the date/time/initials. Nicotine oral spray (Quickmist ) Dose interval (minimum) Max 4 sprays / hour Dose Route Max 64 sprays in 24 hours 1 2 sprays Oral Signature Date Date Time Dose Initial Date Time Dose Initial 7
8 3. Nicotine replacement therapy products and prices I N C R E A S I N G C O S T Product Strength Pack size Cost per patient per month Niquitin CQ 24 hour patches Nicorette Invisi 16 hour patches 7mg 1 x mg 1 x mg 1 x mg 1 x mg 1 x mg 1 x Product Strength Pack size Cost per patient per month Lozenges 1mg, 2mg and 4mg 1 x Inhalator cartridges 15mg 1 x Quickmist spray 1mg 1 x 150 dose
9 4. Ordering Item code description Purchase price Contract number Category code Category Description Comments NICORETTE ICY MINT LOZENG 2MG (Outer pack of 4 packs of 80) SH0490 ZOR NICORETTE ICY MINT LOZENG 4MG (Outer pack of 4 packs of 80) SH0490 ZOR Lower strength lozenge. These are the most popular lozenge with clients - most palatable Higher strength lozenge. These are the most popular lozenge with clients - most palatable. Most clients will start on higher strength so probably need more of these NICORETTE INHALATOR 15MG WHITE (Outer pack of 12 packs of 4) SH0490 ZOR NICORETTE INHALATOR 15MG WHITE (Outer pack of 6 packs of 36) SH0490 ZOR Starter pack - clients to try product without wasting large box. Can be also be used if client needs a new mouth piece. May want small stock for ongoing use NICORETTE INVISI PATCH 10MG (Outer pack of 6 packs of 7) 16 hour patch SH0490 ZOR NICORETTE INVISI PATCH 15MG (Outer pack of 6 packs of 7) 16 hour patch SH0490 ZOR NICORETTE INVISI PATCH 25MG (Outer pack of 6 packs of 14) 16 hour patch SH0490 ZOR NIQUITIN PATCH STEP 1 21MG CLEAR (Outer pack of 3 packs of 1 X 14 Days) 24 hour patch SH0490 ZOR NIQUITIN PATCH STEP 2 14MG CLEAR (Outer pack of 6 packs of 1 x 7 Days) 24 hour patch SH0490 ZOR NIQUITIN PATCH STEP 3 7MG CLEAR (Outer pack of 6 packs of 1 x 7 Days) 24 hour patch SH0490 ZOR Few clients will use this strength, may want small stock Some clients will use this strength along side oral product or e-cig MAIN 16 HOUR CLEAR PATCH for most clients to start with and use along side oral product or e-cig. For ongoing use MAIN 24 HOUR clear PATCH for most clients to start with and use along side oral product or e-cig. For ongoing use Some clients will use this strength along side oral product or e-cig Few clients will use this strength, may want small stock 9
10 5. Smoking and interactions with medication Tobacco smoke contains polycyclic aromatic hydrocarbons that induce certain hepatic enzymes (most notably CYP1A2) (13). For some drugs smoking significantly reduces plasma levels of affected medications (13). Therefore higher doses of those medications are needed in people who smoke, compared with people who do not smoke (13). When someone stops smoking enzyme activity reduces over the course of a week (13). It is important to note that NRT does not have any effect on this process (13). Plasma levels of the affected medications will then rise, sometimes substantially (13). Therefore dose reductions are usually necessary (13). If the person restarts smoking, enzyme activity increases, plasma levels of the affected medications fall and hence, dose increases are required (13). This process is complicated and additionally so as the effects are difficult to predict (13). Further complexity is introduced by intermittent smoking (13). Close monitoring of plasma levels, clinical progress and adverse effects is essential (13). Some of the medications that could be affected by a patient stopping smoking (or temporarily abstaining from smoking) are listed in the table on the following page (adapted from The Maudsley Guideline, 12 th edition (13) ). This is not an exhaustive list of medications affected by smoking. Please contact your ward pharmacist for further details. When someone changes their smoking status or alters the number smoked or when medications are started / stopped, it is important to liaise closely with the patient s prescriber in hospital and in the community. 10
11 (13, 14) Smoking and interactions with medication (This list is not exhaustive. Discuss with your ward pharmacist for more information) Drug Effect of smoking Action to be taken on stopping smoking Action to be taken on re-starting smoking Agomelatine Plasma levels decreased Monitor closely. May need to decrease dose. Consider re-introducing previous smoking dose. Aminophylline / theophylline Levels decreased. Obtain level. Consider decreasing dose by 25 33% after one week. Anticipate the need for further dose reductions over future weeks / months. Monitor closely. May need to decrease dose. Monitor closely. Consider decreasing dose by up to 25% over one week. Monitor for changes in severity of adverse effects. Obtain level. Adjust dose as necessary and monitor closely. Beta blockers Effect of beta blockers decreased. Monitor closely. May need to adjust dose. Benzodiazepines Plasma levels decreased by Monitor closely. Consider restarting 0 50%. previous smoking dose. Carbamazepine Levels may be decreased to Monitor plasma levels. a small extent. Chlorpromazine Levels decreased. Monitor closely. Consider decreasing dose. Monitor closely. Consider restarting previous smoking dose. Clozapine Plasma levels decreased by Obtain clozapine level before stopping. On Obtain level before restarting. up to 50%. Effect may be stopping, decrease dose gradually over a Increase dose to previous smoking greater if co-prescribed week by 25%. Repeat level one week after dose over one week. Repeat level valproate. stopping. Anticipate further dose reductions. after one week on new dose. Duloxetine Levels may be decreased by up to 50%. Monitor closely. Dose may need to be decreased. Flecainide Decreases flecainide levels. Monitor for flecainide adverse effects (eg, dizziness, nausea, tremor). May need to decrease flecainide dose. Fluphenazine Levels decreased by up to Decrease dose by 25%. Monitor carefully 50%. during the next 4 8 weeks. Consider Fluvoxamine Haloperidol Mirtazapine Olanzapine Opioids, including methadone Theophylline / aminophylline Tricyclic antidepressants Levels decreased by approx one third. Levels decreased by approx 20%. Unclear, but effect probably minimal. Levels decreased by up to 50%. Opioid effectiveness decreased. Levels decreased. Levels decreased by 25 50%. further dose reductions. Monitor closely. May need to decrease dose. Decrease dose by approx 10%. Monitor carefully. Consider further dose reductions. Monitor. Obtain level before stopping. On stopping, decrease dose by 25%. After one week, repeat plasma level. Consider further dose reductions. Monitor for adverse effects and signs of opioid toxicity. Consider decreasing the dose. Obtain level. Consider decreasing dose by 25 33% after one week. Anticipate the need for further dose reductions over future weeks / months. Monitor closely. Consider decreasing dose by 10 25% over one week. Consider further dose reductions. Consider re-introducing previous smoking dose. Monitor closely. May need to increase flecainide dose to previous smoking dose. Increase dose to previous smoking dose. May need to increase dose to previous smoking dose. Increase dose to previous smoking dose. Monitor. Obtain level before restarting. Increase dose to previous smoking dose over one week. Repeat plasma level. Monitor for effectiveness. Consider increasing the dose gradually. Obtain level. Adjust dose as necessary and monitor closely. Monitor closely. Consider restarting previous smoking dose. Warfarin INR may be decreased. Monitor INR closely. May need to alter dose. Monitor INR closely. May need to alter dose. Zuclopenthixol Unclear, but effect probably minimal. Monitor. Monitor. 11
12 6. Precautions for use of NRT Cardiovascular / cerebrovascular disease: Patients in hospital with a myocardial infarction, severe arrhythmia or stroke and who are haemodynamically unstable and / or who have uncontrolled hypertension, should be encouraged to stop smoking without NRT (3, 4, 5, 6, 9). If this fails, these patients should be offered NRT under medical supervision (3, 4, 5. 6, 9, 10, 11, 12). Diabetes: Blood glucose levels may destabilise when stopping smoking or abstaining from smoking 9, 10, 15). This is because catecholamines released by nicotine can affect carbohydrate metabolism 10, 15). Blood glucose levels should be monitored closely when using NRT (2, 3, 4, 5, 6, 10, 11, 15). Renal and hepatic impairment: NRT should be used with caution in patients with moderate / severe hepatic impairment and / or severe renal impairment (9, 10). This is because the clearance of nicotine or (3, 4, 5, 6, 9, its metabolites may be decreased, thereby potentially leading to an increase in adverse effects 10, 11). Gastrointestinal disease: Swallowed nicotine (from swallowed spray, lozenges or inhalator) may exacerbate oesophagitis, gastritis, gastric or peptic ulcers, oral or pharyngeal inflammation (9, 10, 11, 12). Oral NRT preparations should be used with caution in patients with these conditions (2, 9, 10, 11, 12). Phaeochromocytoma and uncontrolled hyperthyroidism: NRT should be used with caution in patients with these conditions as nicotine causes the release of catecholamines (4, 5, 6, 9, 10, 11, 12, 15). Lung disease: Patients with obstructive lung disease may find the inhalator difficult to use. A nicotine patch, oral spray or lozenge may be preferred. Nicorette inhalator should be used with caution in patients with chronic throat disease, bronchospastic disease and obstructive lung disease (2). Seizures: Potential risks and benefits of nicotine should be carefully evaluated before use in patients taking antiepileptics or in those with a history of epilepsy, as convulsions have been reported in association with nicotine (3, 4, 11). Broken skin /skin disorders: NRT patches should not be placed on broken skin (2, 3, 4), and they should not be used by patients with skin disorders (2, 5, 6, 7). Atopic or eczematous dermatitis (due to localised patch sensitivity): In the case of severe or persistent local reactions at the site of application (eg, severe erythema, pruritus or oedema) or a generalised skin reaction (eg urticarial, hives or generalised skin rashes) nicotine patches should be discontinued and medical review obtained (3, 4, 5, 6, 7). Most warnings for NRT also apply to continued cigarette smoking (2). However, the risk of continued smoking outweighs any risks of using NRT preparations (2). (3, 4, (2, 3, 4, 12
13 7. Side effects of NRT products (2, 3, 4, 5, 6, 9, 11, 15) This list is not exhaustive. Please refer to the relevant manufacturer s data sheet ( or the BNF for a more complete list for each product. Patch (adverse Oral spray Lozenge Inhalator effects common in first 2 3 weeks) Urticaria Itching Burning, tingling, numbness Swelling Pain Interference with taste Headache Hiccups Throat / mouth /tongue irritation Dry mouth Burning lips Indigestion Nausea Increased salivation Blurred vision 8. Use of NRT in pregnancy / lactation Please refer to your ward pharmacist prior to prescribing / administering NRT to a patient who is pregnant or lactating. It is important that current advice is obtained from specialist reference sources. 13
14 9. References 1) Southern Health NHS Foundation Trust Clozapine Guideline SH CP 114 Version 2 (October 2016) Accessed 13 th June ) Royal Pharmaceutical Society and British Medical Association British National Formulary 72 September 2016 March ) data sheet NiQuitin 14mg transdermal patch 4) data sheet NiQuitin 7mg transdermal patch 5) data sheet Nicorette Invisi 15mg patch 6) data sheet Nicorette Invisi 25mg patch 7) NICE guideline PH48 Smoking: acute, maternity and mental health services (November 2013) 8) NICE Public Health guideline PH10 Stop Smoking (November 2013) 9) data sheet Nicorette quickmist oral spray 1mg 10) data sheet Nicotinell mint lozenges 2mg 11) data sheet NiQuitin minis mint lozenges 4mg 12) data sheet Nicorette 15mg inhalator 13) Taylor, D; Paton, C; Kapur, S (2015) The Maudsley Prescribing Guidelines in Psychiatry 12 th edition Wiley Blackwell Chichester 14) e-stockley Accessed 15 th June ) data sheet NiQuitin 21mg transdermal patch 14
SECTION 17: NICOTINE REPLACEMENT. Formulary and Prescribing Guidelines
SECTION 17: NICOTINE REPLACEMENT Formulary and Prescribing Guidelines 17.1 Introduction These guidelines should be used in conjunction with EPUT No Smoking Policy (HRP20) for service users who are 12 years
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 17: NICOTINE REPLACEMENT THERAPY 17.1 Introduction These guidelines should be used in conjunction with SEPT No Smoking Policy (HRP20) and for service users
More informationStop smoking products guidance
Stop smoking products guidance Ref: Status: Approved Stop smoking products guidance Page 1 of 15 Approval date: 22 November 2018 Contents 1. Purpose... 3 2. Related documents... 3 3. Guidance... 3 3.1
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Derbyshire Formulary for Nicotine Replacement Therapy (NRT) 1. Supporting Smokers to stop smoking The most effective method to quit smoking is by quitting
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services SMOKING CESSATION Introduction NICE recommends that Nicotine Replacement Therapy (NRT), bupropion [Zyban ] and
More informationTitle: Approved By: Applicable to: Group D&T section of the AMD Dept./ Division Only No Directorate Only: No Trust-wide No
Title: CLINICAL GUIDELINES ID TAG Smoking Cessation Guideline for the Prescribing, Issue and Administration of Nicotine Replacement Therapy on Inpatient Wards Lyn Watt Pharmacy Patient Services Manager
More informationProtocol for the Direct Supply of Nicotine Replacement Therapy by Competent Non-Clinical Advisors of The Stop Smoking Service in Norfolk
Appendix B Protocol for the Direct Supply of Nicotine Replacement Therapy by Competent Non-Clinical Advisors of The Stop Smoking Service in Norfolk Document Control Document name Protocol for the direct
More informationProcedure for Nicotine Replacement Therapy on Inpatient Units
Procedure for Nicotine Replacement Therapy on Inpatient Units PROCEDURE NO CL 005????? DATE RATIFIED December 2014 REVIEW DATE December 2017 APPROVED BY Drugs and Therapeutics ACCOUNTABLE DIRECTOR Chief
More informationPGD5717. Director of Quality & Clinical Performance. Therèsa Moyes
PGD5717 Patient Group Direction Administration of Nicotine Lozenges 4mg, Sublingual Tablets 2mg or Mouth Spray By Registered Nurses employed as by South Staffordshire & Shropshire Healthcare Foundation
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationSmoking and Nicotine Replacement Therapy (NRT) Lec:5
Smoking and Nicotine Replacement Therapy (NRT) Lec:5 Tobacco use remains the single largest preventable cause of mortality. Cigarette smoke is a complex mixture of an estimated 4800 compounds. Approximately
More informationNicotine Replacement Therapy (NRT).
Nicotine Replacement Therapy (NRT). Information for smokers 1 What is NRT? The aim of Nicotine Replacement Therapy (NRT) is to reduce the withdrawal symptoms associated with nicotine addiction by replacing
More informationThis letter authorises the extended use of the following protocol until 1st September 2018:
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date: 22nd March 2018 Our Ref: FA/NRTComm/MGPG/Mar18 Enquiries to: Frances Adamson Extension: 56689 Direct Line: 01224
More informationTobacco Dependence Treatment Pathway
Tobacco Dependence Treatment Pathway GUIDELINE VERSION 1 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED January 2017 NEXT REVIEW DATE January 2019 FORMULARY SPONSOR Executive Medical
More informationGuidance for the Management of Smoking Cessation within Sirona Care & Health and Providers in the Community
Guidance for the Management of Smoking Cessation within Sirona Care & Health and Providers in the Community This guidance should be used in close conjunction with the referenced guidelines, in particular
More information5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.
0 11 Key Messages 1. Ask and document smoking status for all patients. 2. Provide brief advice on quit smoking at every visit to all smokers. 3. Use individual, group and telephone counselling approaches,
More informationNHS FORTH VALLEY Stop Smoking Guidance
NHS FORTH VALLEY Stop Smoking Guidance Date of First Issue 28/06/2012 Approved 28/06/2012 Current Issue Date 22/01/2018 Review Date 22/01/2021 Version Version 2 EQIA 01/05/2018 Author / Contact Scott Robertson,
More informationMy Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.
My Mask KL I keep it all inside Because I d rather The pain destroy me Than everyone else. Anon. 43 K. N. Roy Chengappa, M.D., FRCPC Professor of Psychiatry, University of Pittsburgh School of Medicine,
More informationNicotine Replacement Therapy, Zyban and Champix. Name of presentation
Nicotine Replacement Therapy, Zyban and Champix Nicotine Replacement Therapy (NRT) - Rationale for use Nicotine is highly addictive and causes unpleasant withdrawal symptoms which often undermine a quit
More informationMEDICAL DIRECTIVE Title: Administration of Nicotine Replacement Therapy by Health Professionals at Pinewood Centre of Lakeridge Health
Approved by/date: Medical Advisory Comm. Mar 25, 2014 Authorizing physician(s)/nurse practitioner Dr Eli Sagi, Chief of Psychiatry, Medical Director, Mental Health and Pinewood Centre Dr. Ihab Sorial,
More informationGuidelines for. Nicotine Replacement Therapy. Issuing of Vouchers. For use by the Stop Smoking in Pregnancy Service
Guidelines for Nicotine Replacement Therapy Issuing of Vouchers For use by the Stop Smoking in Pregnancy Service DOCUMENT CONTROL: Version: 1 Ratified by: Clinical Effectiveness Committee Date ratified:
More informationPackage leaflet: Information for the user. Nicovel Frukt 4 mg medicated chewing-gum. nicotine
Package leaflet: Information for the user Nicovel Frukt 2 mg medicated chewing-gum Nicovel Frukt 4 mg medicated chewing-gum nicotine Read all of this leaflet carefully before you start using this medicine
More informationPrescribing guidance in. Smoking Cessation March 2011
Prescribing guidance in Smoking Cessation March 2011 The aim of this guidance is to update previous prescribing guidance (2007) ensuring that there is a consistent approach throughout Dumfries & Galloway
More informationBest Practice for Smoking Cessation: Pharmacotherapy. Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree
Best Practice for Smoking Cessation: Pharmacotherapy Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree Why is it so hard to quit? People who smoke aren t weak
More informationSmoking cessation therapy
Appendix 1 Smoking cessation therapy Q. Can a dentist prescribe medications for smoking cessation? A. Yes. Dentists are allowed and are encouraged to help patients with smoking cessation by counseling
More information6.2 Overview of disease epidemiology
6.2 Overview of disease epidemiology WHO has calculated that every second smoker will die early because of smoking and in average a smoker will lose 7-8 years of lifetime. Today, tobacco use causes 1 in
More informationPROCEDURE: SABP/EXECUTIVE BOARD/0017/PROCEDURE 11. Administration
PROCEDURE: SABP/EXECUTIVE BOARD/0017/PROCEDURE 11 NAME OF PROCEDURE: REASON FOR THE PROCEDURE: WHAT THE PROCEDURE WILL ACHIEVE: Medicines Procedure: Homely Remedies Administration Guidance on administration
More informationPackage leaflet: Information for the user. Nicotinell Tropisk frukt 4 mg medicated chewing-gum
Package leaflet: Information for the user Nicotinell Tropisk frukt 2 mg medicated chewing-gum Nicotinell Tropisk frukt 4 mg medicated chewing-gum nicotine Read all of this leaflet carefully before you
More informationPatient Group Direction for the Supply of Nicotine Replacement Therapy, (NRT) (Smoking Cessation Service for Pharmacies in Kent)
Patient Group Direction for the Supply of Nicotine Replacement Therapy, (NRT) (Smoking Cessation Service for Pharmacies in Kent) Written by: Marion Walton, Pharmacist Advanced, Adult Services Date: February
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationCAMBRIDGESHIRE & PETERBOROUGH STOP SMOKING SERVICE S. Stop Smoking Pharmacological Products Guidance
CAMBRIDGESHIRE & PETERBOROUGH STOP SMOKING SERVICE S Stop Smoking Pharmacological Products Guidance This guidance is for use by Cambridgeshire Stop Smoking Service (CAMQUIT), Peterborough Stop smoking
More informationBoots NicAssist Fruit Fresh Gum (Nicotine)
Information for the user Boots NicAssist Fruit Fresh Gum (Nicotine) Boots NicAssist Fruit Fresh 2 mg Gum Boots NicAssist Fruit Fresh 4 mg Gum Read all of this leaflet carefully because it contains important
More informationIMPORTANT POINTS ABOUT MEDICATIONS
IMPORTANT POINTS ABOUT MEDICATIONS The U.S. Food & Drug Administration (FDA) advises that there are significant health benefits to quitting smoking. The health benefits of quitting smoking include a reduction
More informationCessation of Smoking By Nicotine Replacement Therapy
Review Article ISSN: 0974-6943 Mamatha. J et al / Journal of Pharmacy Research 2017,11(5), Available online through http://jprsolutions.info Cessation of Smoking By Nicotine Replacement Therapy Mamatha.
More informationCustomize Your Quit \ 2 1 / Tailored treatment to help stop smoking. Customize Your Quit. Customize Your Quit
1 / \ 2 Customize Your Quit McNeil Consumer Healthcare, division of Johnson & Johnson Inc., Markham, Canada L3R 5L2 Johnson & Johnson Inc. 2017 PSNRT15-80E Tailored treatment to help stop smoking 3 / \
More informationNicAssist 2 mg Lozenge (Nicotine)
Information for the user NicAssist 2 mg Lozenge (Nicotine) Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription to help
More informationInhalator Nicotine Replacement Therapy
NICORETTE (NRT) Inhalator Nicotine Replacement Therapy What is NICORETTE? NICORETTE is a range of NRT medicines intended to support you while you give up smoking by relieving withdrawal symptoms and reduce
More informationPROTOCOL FOR A NICOTINE REPLACEMENT THERAPY (NRT) VOUCHER SCHEME
PROTOCOL FOR A NICOTINE REPLACEMENT THERAPY (NRT) VOUCHER SCHEME PREPARED BY: Kirklees Public Health on behalf of the Council of the Borough of Kirklees FIRST ISSUED: 1 st April 2017 TO BE REVIEWED: 31
More informationSMOKING CESSATION. Recommendations 5As Approach to Smoking Cessation. Stages of Change Assisting the Smoker. Contributor Dr. Saifuz Sulami.
SMOKING CESSATION 08 Recommendations 5As Approach to Intervention Stages of Change Assisting the Smoker Pharmacotherapy Contributor Dr. Saifuz Sulami Advisor Dr. Audrey Tan 79 nhg_guideline_14102010_1112.indd
More informationCENTRE FOR ADDICTION AND MENTAL HEALTH -MEDICAL DIRECTIVE ADMINISTRATION OF NICOTINE REPLACEMENT MEDICATIONS BY REGISTERED NURSES
CENTRE FOR ADDICTION AND MENTAL HEALTH -MEDICAL DIRECTIVE TITLE: ADMINISTRATION OF NICOTINE REPLACEMENT MEDICATIONS BY REGISTERED NURSES POLICY #: D24 ORIGINATOR: Nicotine Dependence Clinic APPROVAL DATE:
More informationPackage leaflet: Information for the user. Zonnic Mint 2 mg oromucosal powder in pouch Nicotine
Package leaflet: Information for the user Zonnic Mint 2 mg oromucosal powder in pouch Nicotine Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationStandard operating procedure for the use of nicotine replacement therapy (NRT) products
Appendix B Standard operating procedure for the use of nicotine replacement therapy (NRT) products Parent Policy / Policies Health and Social Care Act 2012 Brighton and Hove Health and Wellbeing Strategy
More informationCessation Medicine Reference Guide Table of Contents
Cessation Medicine Reference Guide Table of Contents 1. Patch 2. Nicotine Gum 3. Nicotine Lozenge 4. Inhaler 5. Nasal Spray 6. Bupropion SR (Zyban) 7. Chantix (Varenicline) Patch Typical course of therapy
More informationSMART STEPS towards a tobacco-free life
SMART STEPS towards a tobacco-free life Ready to Quit Smoking? You decide when. We ll show you how. Smart steps... Ready to Put Tobacco Behind You? Congratulations on deciding to quit! Quitting tobacco
More informationNICOTEX Chewing Gum (Nicotine polacrilex)
Published on: 22 Sep 2014 NICOTEX Chewing Gum (Nicotine polacrilex) Composition NICOTEX Chewing Gum Each piece contains: Nicotine Polacrilex USP (equivalent to Nicotine)... 2 mg or Nicotine Polacrilex
More informationEffective date: October 15, 2009
COLLECTIVE PRESCRIPTION Start According to a protocol: Yes No Effective date: October 15, 2009 Next review date: October 15, 2012 Professionals who can dispense the prescription Community pharmacists working
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Nicotinell Mint 1 mg compressed lozenges 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each piece of lozenge contains: Active substance:
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER
More informationPackage leaflet: information for the user Nicorette Microtab 2 mg sublingual tablets. Nicotine
Nicorette Microtab for packaging containing blister Package leaflet: information for the user Nicorette Microtab 2 mg sublingual tablets Nicotine Read all of this leaflet carefully before you start using
More informationNicAssist 1mg/spray Mouth Spray Nicotine
Information for the user NicAssist 1mg/spray Mouth Spray Nicotine Read all of this leaflet carefully before you start using this medicine because it contains important information for you. This medicine
More informationAWMSG members are asked to consider the update of the All Wales Guide: Pharmacotherapy for Smoking Cessation for endorsement.
Enclosure No: Agenda Item No: Author: Contact: 10/AWMSG/0218 15 All Wales Guide: Pharmacotherapy for Smoking Cessation Rosemary Allgeier, Principal Pharmacist in Public Health, Public Health Wales Tel:
More information1. WHAT NICOTINELL SPEARMINT CHEWING-GUM IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER Nicotinell Spearmint 2 mg and 4 mg medicated chewing-gum Nicotine Read all of this leaflet carefully because it contains important information for you. This medicine
More informationPharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1
Pharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1 Compiled by: TOP, in collaboration with Dr. Charl Els and Mr. Ron Pohar: TRaC II (Alberta Medical Association/Primary
More informationClearing the Air: What You Need to Know and Do to Prepare to Quit Smoking
Clearing the Air: What You Need to Know and Do to Prepare to Quit Smoking Getting Ready to Quit Course Creating Success! THINK ABOUT Process of Changing an Addiction Your Pros and Cons of Smoking and Quitting
More informationWhite to yellowish chewing-gum, slightly convex, rectangular with an approximate size of mm.
1. NAME OF THE MEDICINAL PRODUCT Nikorono Frukt 2 mg medicated chewing-gum Nikorono Frukt 4 mg medicated chewing-gum 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Nikorono Frukt 2 mg: Each chewing-gum contains
More informationNicAssist 15 mg Inhalator (Nicotine)
Information for the user NicAssist 15 mg Inhalator (Nicotine) Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription to help
More informationStandard Operating Procedure 1 (SOP 1) Clinical Guidelines for Prescribing Nicotine Replacement Therapy In Smoking Cessation
Standard Operating Procedure 1 (SOP 1) Clinical Guidelines for Prescribing Nicotine Replacement Therapy In Smoking Cessation Background Smoking kills 50% of lifetime smokers through causing cancer, heart
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE (Approved May 2014 - Review Date May 2016) GENERAL POLICY PATIENT GROUP DIRECTION
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationOutpatient Tobacco Addiction Treatment Pathway Additional Notes
Outpatient Tobacco Addiction Treatment Pathway Additional Notes First Line: Varenicline (provide in conjunction with counselling/support, but if such support is refused or is not available, this should
More informationPRODUCT INFORMATION. NICORETTE INHALATOR Nicotine Inhalation 15 mg per cartridge
NAME OF THE MEDICINE Nicotine DESCRIPTION PRODUCT INFORMATION NICORETTE INHALATOR Nicotine Inhalation 15 mg per cartridge NICORETTE Inhalator consists of a porous plug of polyethylene which contains nicotine
More informationBRIGHTON & HOVE NICOTINE REPLACEMENT THERAPY (NRT) VOUCHER SCHEME
BRIGHTON & HOVE NICOTINE REPLACEMENT THERAPY (NRT) VOUCHER SCHEME A voucher scheme is commonly used instead of, or sometimes as well as, GP prescriptions (FP10) and PGDs. The Brighton & Hove nicotine replacement
More informationSUMMARY OF PRODUCT CHARACTERISTICS. One spray delivers 1 mg nicotine in 0.07 ml solution. 1 ml solution contains 13.6 mg nicotine.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Nicorette Pepparmint 1 mg/spray, oromucosal spray, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One spray delivers 1 mg nicotine
More informationAIDS for CESSATION PHARMACOTHERAPY. METHODS for QUITTING. NONPHARMACOLOGIC METHODS (cont d) NONPHARMACOLOGIC METHODS
METHODS for QUITTING AIDS for CESSATION Nonpharmacologic Counseling and other non-drug approaches Pharmacologic FDA-approved medications Counseling and medications are both effective, but the combination
More informationSmoke-free Hospitals. Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service
Smoke-free Hospitals Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service Today s Subjects 5A s and Clinician Training and Use with the Hospitalized Patient NRT use in
More informationTherapy Activation Date: Review Date:
MEDICAL DIRECTIVE Title: Nicotine Replacement Number: TCFHT-MD10 Therapy Activation Date: 14-06-2011 Review Date: 01-05-2016 Sponsoring/Contact Person(s) (name, position, contact particulars): Sherry Kennedy,
More informationNYSMPEP Smoking Cessation Guidance: Key Message 3
NYSMPEP Smoking Cessation Guidance: Key Message 3 Key Message 3: All smokers trying to quit should be offered medication (except when contraindicated or for specific populations). The Agency for Healthcare
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationService Specification & Contract Intermediate Stop Smoking Service & Voucher fulfilment - Pharmacy Newcastle
Service Specification & Contract Intermediate Stop Smoking Service & Voucher fulfilment - Pharmacy Newcastle Contents 1. Agreement period 2. Scope 3. Targets 4. Service outline 5. Support for clients using
More informationMedication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019
Medication Management to Aid in Smoking Cessation Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019 1 Learning Objectives: Review the prevalence of tobacco use. Describe tools
More informationHealth Professional Manual
Health Professional Manual Session: Smoking Cessation Smoking and COPD Strategies for quitting smoking Adapted from the Living Well with COPD program (2nd edition), Montreal Chest Institute, Canada SESSION
More informationDispensing of Nicotine Replacement Therapy (NRT)
Simcoe Muskoka District Health Unit Print Version Medical Directive Number: Topic: Dispensing of Nicotine Replacement Therapy (NRT) Revised: October 2011 Approved: May 21, 2007 Description Nicotine Replacement
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute
More informationClozapine intramuscular (IM) Guideline, inpatients only
SH CP 203 Clozapine intramuscular (IM) Guideline, inpatients only Summary: Guideline for use and monitoring of intramuscular clozapine treatment. Keywords: Target Audience: Clozapine, intramuscular, IM,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nicotinell Tropisk frukt 2 mg medicated chewinggum Nicotinell Tropisk frukt 4 mg medicated chewinggum 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationin Lincolnshire October 2014 GUIDANCE ON smoking cessation erapy. Nicotine date; at between Nicotine t, patient
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioningg Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
More informationPregnancy and nicotine replacement therapy (NRT) What you need to know
Pregnancy and nicotine replacement therapy (NRT) What you need to know Pregnancy is a great opportunity to stop smoking. Avoiding tobacco is the most important thing a woman can do to improve her health
More informationNICORETTE QuickMist - Nicotine Replacement Therapy (NRT)
QuickMist - Nicotine Replacement Therapy (NRT) Consumer Medicine Information What is? is a range of NRT medicines intended to support you while you give up smoking by relieving withdrawal symptoms and
More informationA new model for prescribing varenicline
Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand
More informationTobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing
Tobacco Dependence Screening and Treatment in Behavioral Health Settings Prescribing GOAL To build the capacity of prescribing clinicians in behavioral health settings to integrate best practices for prescribing
More informationReady to give up. Booklet 3
Ready to give up Booklet 3 This booklet is written for people who have decided that they want to stop smoking. You can use this booklet on its own or go through it with the person who gave it to you. You
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE
More informationSHARED CARE AGREEMENT: MELATONIN (CHILDREN)
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate
More informationTREATMENT INTERVENTIONS
SMOKING CESSATION TREATMENT INTERVENTIONS Smoking and Health Tobacco is the single most preventable cause of death in the world today. kills more than five million people By 2030, the death toll will exceed
More informationBarbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Marie de Haan & Barbara Cadario NICOTINE
Volume 29 (2) 2009 Editor: Barbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Contents - Nicotine Marie de Haan & Barbara Cadario Chairman, Medical Review Laird Birmingham, M.D., M.H.Sc., F.R.C.P.(C) NICOTINE
More informationAIDS for CESSATION PHARMACOTHERAPY. METHODS for QUITTING. NONPHARMACOLOGIC METHODS (cont d) NONPHARMACOLOGIC METHODS
METHODS for QUITTING AIDS for CESSATION Nonpharmacologic Counseling and other non-drug approaches Pharmacologic FDA-approved medications Counseling and medications are both effective, but the combination
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Zonnic Pepparmint 1mg/spraying, oromucosal spray SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 0.07 ml contains 1 mg nicotine, which corresponds
More informationPackage leaflet: Information for the user. Zonnic Pepparmint 1 mg/spraying oromucosal spray Nicotine
Package leaflet: Information for the user Zonnic Pepparmint 1 mg/spraying oromucosal spray Nicotine Read all of this leaflet carefully before you start using this medicine because it contains important
More informationThere are many benefits to quitting for people with cancer even if the cancer diagnosis is not tobacco-related INCREASED
Stopping tobacco use reduces your risk for disease and early death. There are health benefits at any age. YOU ARE NEVER TOO OLD TO QUIT. Health benefits begin immediately. INCREASED blood oxygen levels
More informationQuit with Us. Service Evaluation. August 2016
Quit with Us Service Evaluation August 2016 Contents 1. Executive Summary... 1 2. Introduction... 1 3. Background... 1 4. Data Collection Methods... 1 5. Results... 1 6. Preferred smoking quit methods...
More informationPackage leaflet: information for the user. Nicorette Frukt 2 mg compressed lozenges Nicorette Frukt 4 mg compressed lozenges nicotine
Package leaflet: information for the user Nicorette Frukt 2 mg compressed lozenges Nicorette Frukt 4 mg compressed lozenges nicotine Read all of this leaflet carefully before you start taking this medicine
More informationPATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists
PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of
More informationSmoking and your health and wellbeing
Smoking and your health and wellbeing Your reasons for quitting You can quit here s how Staying smoke-free Smoke-free support It s great being free from that addiction my children are delighted Going smoke-free
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationTobacco Cessation The Role of the Dentist/Oral Medicinist
Tobacco Cessation The Role of the Dentist/Oral Medicinist Jennifer Frustino, DDS PhD Oral Oncology & Maxillofacial Prosthetics Erie County Medical Center Buffalo, NY Statement of Disclosure I have no actual
More information7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5
7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5 2 / 5 3 / 5 7 day quit smoking pdf 7 Your guide to quitting smoking This guide is for smokers who want to quit and stay quit. Just like
More informationQuitX Chewing Gum (Freshmint and Classic flavour) 2mg & 4mg Nicotine Chewing Gum
QuitX Chewing (Freshmint and Classic flavour) 2mg & 4mg Nicotine Chewing Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about QuitX gums. It does not contain
More information